Insider Selling: Momenta Pharmaceuticals President Sells 1,768 Shares of Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler sold 1,768 shares of the stock on the open market in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $11.54, for a total transaction of $20,402.72. Following the transaction, the president now directly owns 370,518 shares in the company, valued at approximately $4,275,778. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 2.74% on Tuesday, hitting $12.00. The stock had a trading volume of 61,649 shares. Momenta Pharmaceuticals has a 52 week low of $9.85 and a 52 week high of $19.90. The stock’s 50-day moving average is $11.24 and its 200-day moving average is $12.70. The company’s market cap is $617.8 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals’s revenue was up 151.1% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals will post $-1.14 earnings per share for the current fiscal year.
MNTA has been the subject of a number of recent research reports. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Momenta Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.20.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Receive News & Ratings for Momenta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.